• LAST PRICE
    1.2500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.2300/ 3
  • Ask / Lots
    1.2700/ 26
  • Open / Previous Close
    1.2500 / 1.2500
  • Day Range
    Low 1.2100
    High 1.2500
  • 52 Week Range
    Low 1.0300
    High 2.2100
  • Volume
    47,678
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.25
TimeVolumeBDSX
09:32 ET8311.25
09:45 ET28001.24
10:01 ET32001.24
11:06 ET1001.23
11:27 ET1001.235
11:42 ET5751.24
11:58 ET1001.24
12:23 ET2001.24
12:43 ET25001.25
01:14 ET48491.23
01:15 ET2781.25
01:53 ET1001.24
01:55 ET11151.245
01:57 ET1001.245
02:40 ET3001.245
02:42 ET1001.24
02:51 ET1531.24
02:58 ET1001.24
03:21 ET106461.24
03:25 ET2501.2301
03:30 ET3501.24
03:39 ET48621.23
03:41 ET11421.21
03:43 ET1001.21
03:50 ET29131.24
03:52 ET3061.24
03:57 ET2131.24
03:59 ET3761.25
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBDSX
Biodesix Inc
142.0M
-1.9x
---
United StatesZOM
Zomedica Corp
121.2M
-3.5x
---
United StatesLDDD
Longduoduo Co Ltd
162.9M
196.4x
---
United StatesPRPH
Prophase Labs Inc
94.9M
-5.5x
---
United StatesJYNT
Joint Corp
180.0M
-18.4x
---
United StatesCDIX
Cardiff Lexington Corp
70.9M
-635.4x
---
As of 2024-04-20

Company Information

Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Contact Information

Headquarters
Suite 100, 2970 Wilderness PlaceBOULDER, CO, United States 80301
Phone
303-417-0500
Fax
303-417-9700

Executives

Independent Chairman of the Board
John Patience
President, Chief Executive Officer, Director
Scott Hutton
Chief Financial Officer, Treasurer, Secretary
Robin Cowie
Chief Accounting Officer
Christopher Vazquez
Independent Director
Jean Franchi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$142.0M
Revenue (TTM)
$49.1M
Shares Outstanding
113.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.13
EPS
$-0.65
Book Value
$0.05
P/E Ratio
-1.9x
Price/Sales (TTM)
2.9
Price/Cash Flow (TTM)
---
Operating Margin
-84.22%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.